<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3080">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374552</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2020000872</org_study_id>
    <nct_id>NCT04374552</nct_id>
  </id_info>
  <brief_title>Asymptomatic COVID-19 Trial</brief_title>
  <acronym>ACT</acronym>
  <official_title>RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus disease-2019 (COVID-19) is spreading throughout the United States. While&#xD;
      there are no known therapies to treat those who have become sick, there have been some&#xD;
      reports that a medication currently used to treat rheumatoid arthritis, lupus, and malaria&#xD;
      (Hydroxychloroquine sulfate, also known as Plaquenil) may help to lessen the chance or&#xD;
      severity of illness, especially if combined with a medicine that treats other kinds of&#xD;
      infections (Azithromycin, also known as Zithromax or Zmax or Zpak).&#xD;
&#xD;
      There are some people who test positive for the virus but who are otherwise not ill. Current&#xD;
      standard of care is to advise these people to self-monitor but no treatment is offered. It is&#xD;
      not known how many of these individuals will remain symptom free, and how many will become&#xD;
      sick or how severe those symptoms will be. This study will randomize those people who do not&#xD;
      have symptoms into one of three treatment plans 1) Hydroxycholoquine and Azithromycin, or 2)&#xD;
      no active medication (placebo). All participants will be followed for 2 months.&#xD;
&#xD;
      The study will determine if there is any benefit to those who are asymptomatic to taking&#xD;
      taking Hydroxychloroquine sulfate in combination with Azithromycin, or if there is no benefit&#xD;
      from taking these medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized into one of two treatment plans&#xD;
&#xD;
        1. Hydroxycholoquine sulfate in combination with Azithromycin Hydroxycholorquine as above,&#xD;
           plus Azithromycine: 500 mg po for day 1and then 250 mg QD for 4 days&#xD;
&#xD;
        2. no active medication (placebo)&#xD;
&#xD;
      All participants will be followed for 2 months. The primary aim is to determine if there is&#xD;
      any benefit (reduced likelihood for development of fever and other symptoms of COVID-19 ) to&#xD;
      taking only Hydroxychloroquine sulfate, or to taking Hydroxychloroquine sulfate in&#xD;
      combination with Azithromycin, or if there is no benefit to taking these medications for this&#xD;
      population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The investigators have decided not to go forward with this protocol&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 5, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study medication will be tablets containing either active drug or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the rate of decline in viral load over the 10 days after randomization</measure>
    <time_frame>10 days</time_frame>
    <description>Change in SARS-CoV-2 viral from baseline to day 6</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine &amp; Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine sulfate 400 mg po BID for day one and then 400 mg QD for 4 days Azithromycin 500 mg po on day one, followed by 250 mg po QD X 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Hydroxychloroquine sulfate (2 pills bid day one and then 2 tablets QD for 4 days) Placebo for Azithromycin (2 pills on day one and followed by 1 pill po QD x 4 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine sulfate &amp;Azithromycin</intervention_name>
    <description>Drug - Hydroxychloroquine sulfate &amp;Azithromycin</description>
    <arm_group_label>Hydroxychloroquine &amp; Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug - placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented SARS-CoV-2 infection by qPCR assay without symptoms consistent with&#xD;
             COVID-19 within 1 week of enrollment&#xD;
&#xD;
          2. Age â‰¥20&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Retinal eye disease&#xD;
&#xD;
          2. Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency&#xD;
&#xD;
          3. Known chronic kidney disease, stage 4 or 5 or receiving dialysis&#xD;
&#xD;
          4. Current use of:&#xD;
&#xD;
               -  Class 3 AAD - amiodarone, dronaderone, dofetilide, sotalol)&#xD;
&#xD;
               -  Class 1A AAD (procainamide, quinidine, disopyramide)&#xD;
&#xD;
               -  Flecainide&#xD;
&#xD;
               -  chlorpromazine&#xD;
&#xD;
               -  Cilostazol (Pletal)&#xD;
&#xD;
               -  Donepezil (Aricept)&#xD;
&#xD;
               -  Droperidol&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Methadone&#xD;
&#xD;
               -  Ondansetron(Zofran)&#xD;
&#xD;
               -  Thioridazine&#xD;
&#xD;
               -  Macrolides (clarithromycin, erythromycin)&#xD;
&#xD;
               -  Fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)&#xD;
&#xD;
          5. Pregnancy or women who are breast feeding&#xD;
&#xD;
          6. Inability to tolerate oral medications&#xD;
&#xD;
          7. Allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate&#xD;
&#xD;
          8. Allergy to adhesives&#xD;
&#xD;
          9. QTc interval &gt; 450 mSEC for men and women&#xD;
&#xD;
         10. History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT&#xD;
             interval&#xD;
&#xD;
         11. Non-English-speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Carson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 2, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Jeffrey L Carson, MD</investigator_full_name>
    <investigator_title>Distinguished Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

